VistaGen Therapeutics, Inc.

VTGN

Healthcare|Biotechnology|US

$0.16

-0.00 (-0.85%)

DCF Value

$0.69

Tangible Book / Share

$0.57

Cash / Share

$0.74

Clinical Trials (12)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT05030350 Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)	Social Anxiety Disorder	P3	Terminated	481	Open-label	PH94B
NCT04754802 PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge	Social Anxiety Disorder	P3	Completed	224	RCT, Double-blind	PH94B Nasal Spray, Placebo Nasal Spray
NCT06615557 Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)	Social Anxiety Disorder (SAD)	P3	Completed	238	RCT, Double-blind	Fasedienol Nasal Spray, Placebo Nasal Spray
NCT06358651 Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)	Social Anxiety Disorder	P3	Completed	238	RCT, Double-blind	Fasedienol Nasal Spray, Placebo Nasal Spray
NCT05011396 PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2	Social Anxiety Disorder	P3	Terminated	228	RCT, Double-blind	PH94B Nasal Spray, Placebo Nasal Spray
NCT03078322 AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression	Major Depressive Disorder	P2	Completed	180	RCT, Double-blind	AV-101, Placebo
NCT06809179 A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder	Social Anxiety Disorder	P2	Completed	61	RCT, Double-blind	Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray
NCT03583554 Electrophysiological Biomarkers of AV-101	Healthy	P1P2	Completed	18	RCT, Double-blind	Placebo, AV-101 720 mg, AV-101 1440 mg
NCT04404192 PH94B in the Treatment of Adjustment Disorder With Anxiety	Adjustment Disorder With Anxious Mood	P2	Completed	41	RCT, Double-blind	PH94B, Placebo
NCT04147949 AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Parkinson Disease, Dyskinesia, Medication-Induced	P2	Unknown	20	RCT, Double-blind	AV-101, Placebo
NCT05280054 AV-101 Alone and in Combination With Probenecid in Healthy Subjects	Drug Drug Interaction	P1	Unknown	24	Open-label	AV-101, Probenecid
NCT01483846 Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers	Neuropathic Pain	P1	Completed	50	RCT, Double-blind	AV-101, Placebo